Novo Nordisk Q3 adjusted sales hit 79.2B DKK, beating 73.55B forecast

The beat is broad, landing in both the top line and operating profit, but the detail that stands out is oral Wegovy clearing its forecast — a signal that the pill format is gaining commercial traction rather than staying a pipeline story. The full-year guide, still spanning a narrow band around flat constant-currency growth, suggests management is not extrapolating one strong quarter into a re-rating. Whether oral Wegovy's contribution keeps scaling, and whether the guidance band narrows or shifts at the next update, is the open question for observers of the obesity-drug trade.